Private Equity And VC Fund Data: What Do The Numbers Show?

In Vivo examines trends in the venture capital and private equity funding landscapes for biotech and pharma – looking at both expenditure and gathering of capital resources.

2021 was a landmark year for private capital fundraising across many sectors with the excitable market allowing for plentiful, early exits. The biopharma industry saw particular interest as the COVID-19 pandemic drew attention to potential gains to be made from the sector. Has the appetite for investing in drug development waivered now the pandemic has subsided?

Fundraising for biopharma VC looks to have normalized to pre-2018 levels after the giddy heights of 2021, according to In...